Literature DB >> 23625089

Gene silencing of c-Met leads to brain metastasis inhibitory effects.

Se Jeong Lee1, Ho Jun Seol, Hye Won Lee, Won Young Kang, Bong Gu Kang, Juyoun Jin, Mi-Young Jo, Younggeon Jin, Jung-Il Lee, Kyeung Min Joo, Do-Hyun Nam.   

Abstract

An unfortunate consequence of improvements in the treatments of advanced primary cancers is the concurrent increase of metastatic brain tumors. Despite of unfavorable clinical prognosis, radiation therapy is still the only viable treatment option for brain metastases. Expression of c-Met induces cell migration and invasion in many cancers, which are indispensable steps for metastasis. Accordingly, we examined the effects of gene silencing of c-Met on brain metastasis to evaluate the possibility of c-Met as a potential target. MDA-MB-435 cells were transfected with c-Met targeting short hairpin RNAs (shRNAs). Effects of c-Met shRNAs on the expression of epithelial mesenchymal transition (EMT) related proteins, in vitro migration, and in vivo brain metastasis were examined. Expression of mesenchymal markers and in vitro migration of MDA-MB-435 cells were significantly inhibited by introduction of c-Met shRNAs. When c-Met-silenced MDA-MB-435 cells were stereotactically implanted into the brains of immune-compromised mice or injected into the right internal carotid arteries, c-Met-silenced MDA-MB-435 cells produced significantly smaller tumor masses or survival time was significantly prolonged, respectively, compared with MDA-MB-435 cells transfected with control shRNA. The data reveal the novel function of c-Met in the process of brain metastasis and its potential as a preventive and/or therapeutic target in this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23625089     DOI: 10.1007/s10585-013-9584-7

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  24 in total

Review 1.  Met, metastasis, motility and more.

Authors:  Carmen Birchmeier; Walter Birchmeier; Ermanno Gherardi; George F Vande Woude
Journal:  Nat Rev Mol Cell Biol       Date:  2003-12       Impact factor: 94.444

2.  Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.

Authors:  Elisa Benedettini; Lynette M Sholl; Michael Peyton; John Reilly; Christopher Ware; Lenora Davis; Natalie Vena; Dyane Bailey; Beow Y Yeap; Michelangelo Fiorentino; Azra H Ligon; Bo-Sheng Pan; Victoria Richon; John D Minna; Adi F Gazdar; Giulio Draetta; Silvano Bosari; Lucian R Chirieac; Bart Lutterbach; Massimo Loda
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

3.  Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

Authors:  Falko Hochgräfe; Luxi Zhang; Sandra A O'Toole; Brigid C Browne; Mark Pinese; Ana Porta Cubas; Gillian M Lehrbach; David R Croucher; Danny Rickwood; Alice Boulghourjian; Robert Shearer; Radhika Nair; Alexander Swarbrick; Dana Faratian; Peter Mullen; David J Harrison; Andrew V Biankin; Robert L Sutherland; Mark J Raftery; Roger J Daly
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

Review 4.  The Met receptor tyrosine kinase and basal breast cancer.

Authors:  Marisa G Ponzo; Morag Park
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

5.  Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.

Authors:  Stéphane Garcia; Jean-Philippe Dalès; Emmanuelle Charafe-Jauffret; Séverine Carpentier-Meunier; Lucile Andrac-Meyer; Jocelyne Jacquemier; Claudine Andonian; Marie-Noëlle Lavaut; Claude Allasia; Pascal Bonnier; Colette Charpin
Journal:  Hum Pathol       Date:  2007-02-20       Impact factor: 3.466

Review 6.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

7.  Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes.

Authors:  Anthony Gonçalves; Emmanuelle Charafe-Jauffret; François Bertucci; Stéphane Audebert; Yves Toiron; Benjamin Esterni; Florence Monville; Carole Tarpin; Jocelyne Jacquemier; Gilles Houvenaeghel; Christian Chabannon; Jean-Marc Extra; Patrice Viens; Jean-Paul Borg; Daniel Birnbaum
Journal:  Mol Cell Proteomics       Date:  2008-04-20       Impact factor: 5.911

8.  Scatter factor/hepatocyte growth factor is essential for liver development.

Authors:  C Schmidt; F Bladt; S Goedecke; V Brinkmann; W Zschiesche; M Sharpe; E Gherardi; C Birchmeier
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

Review 9.  Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.

Authors:  Joseph Paul Eder; George F Vande Woude; Scott A Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

10.  Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis.

Authors:  Stéphane Garcia; Jean-Philippe Dales; Emmanuelle Charafe-Jauffret; Séverine Carpentier-Meunier; Lucile Andrac-Meyer; Jocelyne Jacquemier; Claudine Andonian; Marie-Noelle Lavaut; Claude Allasia; Pascal Bonnier; Colette Charpin
Journal:  Int J Oncol       Date:  2007-07       Impact factor: 5.650

View more
  4 in total

1.  Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.

Authors:  T-H Hung; Y-H Li; C-P Tseng; Y-W Lan; S-C Hsu; Y-H Chen; T-T Huang; H-C Lai; C-M Chen; K-B Choo; K-Y Chong
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

2.  Pan-cancer analysis reveals the role of long non-coding RNA LINC01614 as a highly cancer-dependent oncogene and biomarker.

Authors:  Dingding Wang; Hong Zhang; Xiaolian Fang; Dingfang Cao; Honggang Liu
Journal:  Oncol Lett       Date:  2020-05-20       Impact factor: 2.967

Review 3.  HGF/MET Signaling in Malignant Brain Tumors.

Authors:  Elizabeth Qian Xu Mulcahy; Rossymar Rivera Colόn; Roger Abounader
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

4.  Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.

Authors:  Zheng Wu; Zhe Zhang; Xiaoxiao Ge; Ying Lin; Congqi Dai; Jinjia Chang; Xinyang Liu; Ruixuan Geng; Chenchen Wang; Huan Chen; Menghong Sun; Weijian Guo; Jin Li
Journal:  Oncotarget       Date:  2015-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.